Literature DB >> 29215735

Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.

Angelo Pascarella1,2, Chiara Terracciano3, Olimpia Farina1, Luca Lombardi1, Teresa Esposito4,5, Filomena Napolitano1, Giuseppina Franzese1, Giovanni Panella1, Francesco Tuccillo1, Giancarlo la Marca6, Sergio Bernardini3, Silvia Boffo7, Antonio Giordano7,8, Giuseppe Di Iorio1, Mariarosa A B Melone1,7, Simone Sampaolo1.   

Abstract

Autosomal recessive Pompe disease is a lysosomal disorder caused by mutations of the acid-α-glucosidase (GAA) gene. Deficiency of GAA enzyme leads to glycogen accumulation and autophagy impairment in cardiac and skeletal muscles, but also in lymphocytes. Since an effective therapy is available, a rapid, sensitive, and specific test is crucial to early identify affected subjects. Number of lymphocytes containing PAS-positive vacuoles was evaluated on blood films from 72 consecutive adult patients with hyperckemia and/or muscle weakness, 13 genetically confirmed late-onset-Pompe-disease (LOPD) and 13 of their offspring. GAA activity, measured on dried blood spot (DBS) in all patients inversely correlated with number of PAS-positive lymphocytes. More than 4 PAS-positive lymphocytes were found in 11 out of the 72 patients (6 new diagnosis of LOPD, 3 different glycogen storage myopathies, 1 glucose-6-phosphate dehydrogenase deficiency, 1 caveolinopathy), in all 13 LOPD patients and in the 13 LOPD offspring. These latter resulted to have all a single GAA mutation but low GAA levels. Immunostaining with the autophagy markers LC3 and p62 confirmed the autophagic nature of lymphocytes vacuoles. ROC curve assessment of PAS-positive lymphocytes disclosed 100% of sensitivity and 94% of specificity in recognizing both compound heterozygous and heterozygous GAA carriers. The other myopathies with more than 4 PAS-positive lymphocytes appeared to be all related to impaired autophagy, which seems to be responsible of PAS-positive vacuolated lymphocytes formation. Quantification of PAS-positive lymphocytes in blood films is useful to identify autophagic vacuolar myopathies and should be routinely used as first level test for Pompe disease.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  GSD II diagnostic algorithm; PAS-positive lymphocytic granules; Pompe disease; glycogen storage myopathies; screening method for glycogenosis

Mesh:

Substances:

Year:  2018        PMID: 29215735     DOI: 10.1002/jcp.26365

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  4 in total

Review 1.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

2.  Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD).

Authors:  Daniela Parisi; Olimpia Musumeci; Stefania Mondello; Teresa Brizzi; Rosaria Oteri; Alba Migliorato; Annamaria Ciranni; Tiziana E Mongini; Carmelo Rodolico; Giuseppe Vita; Antonio Toscano
Journal:  Front Neurol       Date:  2018-10-22       Impact factor: 4.003

3.  PDGF-BB serum levels are decreased in adult onset Pompe patients.

Authors:  Esther Fernández-Simón; Ana Carrasco-Rozas; Eduard Gallardo; Sebastián Figueroa-Bonaparte; Izaskun Belmonte; Irene Pedrosa; Elena Montiel; Xavier Suárez-Calvet; Jorge Alonso-Pérez; Sonia Segovia; Claudia Nuñez-Peralta; Jaume Llauger; Mercedes Mayos; Isabel Illa; Jordi Díaz-Manera
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

4.  Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.

Authors:  Filomena Napolitano; Giorgia Bruno; Chiara Terracciano; Giuseppina Franzese; Nicole Piera Palomba; Federica Scotto di Carlo; Elisabetta Signoriello; Paolo De Blasiis; Stefano Navarro; Alessandro Gialluisi; Mariarosa Anna Beatrice Melone; Simone Sampaolo; Teresa Esposito
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.